For a person who loved to hike; do aerobic exercises with Billy Blanks, Gilead, Denise Austin and Jane Fonda every day (I ...
1d
News Medical on MSNContraceptive pill could help reduce risk of ovarian cancer, study suggestsScreening for risk factors of ovarian cancer using artificial intelligence, UniSA researchers found that the oral ...
Hosted on MSN12d
Can a heart failure drug effectively treat a lethal form of ovarian cancer? Scientists hope the answer is 'yes'Knarr of the Penn Ovarian Cancer Research Center, and lead author of the new analysis. "Its high mortality rate is due to the ...
2d
Tennis World on MSNChris Evert shares her 'most frightening' thing about cancer diagnosisChris Evert described not knowing at which stage her cancer was as "the most frightening" thing during her cancer journey as ...
5d
HealthDay on MSNThe Pill Protects Against Ovarian Cancer, Study SaysThe Pill prevents pregnancy -- and maybe ovarian cancer, too, a new study suggests.Women who’ve ever used the contra ...
High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...
13d
News Nation on MSNMother and musician fights ovarian cancer with community helpYawei was initially diagnosed in the United States with a Hernia, after multiple delays it became apparent it was not just a ...
The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...
The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population ...
Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...
Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results